Vous possédez un compte ?
Connectez-vous pour payer plus vite.
Chargement en cours...
mai 2024
juin 2024
Découvre pourquoi tu devrais commencer ton aventure probiotiques avec Bio-K+.
Nos formules scientifiquement étudiées sont conçues pour soutenir votre parcours unique de bien-être
Bacterial vaginosis is among the most common vaginal conditions and the most studied in relation to probiotics. This page covers clinical research on specific strains. BV requires healthcare diagnosis and treatment.
Bacterial vaginosis is characterized by a reduction in dominant Lactobacillus bacteria and an overgrowth of other species, primarily Gardnerella vaginalis and other anaerobic organisms. In a healthy vaginal environment, Lactobacillus produces lactic acid, maintaining an acidic pH inhospitable to pathogenic bacteria. When this balance is disrupted, vaginal dysbiosis BV can develop. BV is diagnosed by a healthcare provider; many women have no symptoms. Antibiotics are the standard treatment. Probiotics are not a replacement for antibiotic therapy.
Lactobacillus is the dominant genus in a healthy vaginal microbiome, protecting the vaginal environment by producing lactic acid, which lowers vaginal pH and creates conditions inhospitable to pathogenic bacteria. Lactobacillus strains also produce hydrogen peroxide and bacteriocin-like substances that inhibit Gardnerella vaginalis (PMC10106725). They adhere to vaginal epithelial cells and competitively exclude pathogenic bacteria from colonizing sites. The loss of Lactobacillus dominance, due to antibiotic use or hormonal shifts, is the central mechanism behind BV.
Research has confirmed that certain Lactobacillus strains taken orally can reach the vaginal tract, ascending from the rectal area to the vagina. Clinical studies have verified this, with orally administered strains detected in vaginal swabs (Optibac; PMC). This explains why oral probiotic capsules with the right strains can interact with the vaginal microbiome. Strain specificity is critical, as not all Lactobacillus strains colonize the vaginal environment.
GR-1™ and RC-14™ are the most extensively studied probiotic strains for women's urogenital health (Canadian Clinical Guide to Probiotic Products). A randomized, double-blind, placebo-controlled trial in 125 women found oral GR-1/RC-14 alongside metronidazole resulted in an 88% cure rate at day 30 versus 40% in the placebo group (PMID 16697231). A separate cohort study found no significant difference; efficacy may be population-specific. Consult a healthcare provider for BV.
BV has a high recurrence rate; up to half of women treated experience recurrence within a year of antibiotic treatment. Antibiotics address acute bacterial overgrowth but can disrupt beneficial Lactobacillus populations. A 2024 review of 16 RCTs identified Lactobacillus rhamnosus as one of the most studied strains for reducing BV recurrence, with some studies showing improvements in vaginal pH and microbiota composition (PMC12059960). Results vary by strain. Consult a healthcare provider for recurring BV.
Strain specificity is critical; look for full genus, species, and alphanumeric designation. GR-1™ and RC-14™ are the most documented strains for women's vaginal flora (Canadian Clinical Guide to Probiotic Products). Confirm CFU is guaranteed until expiry, not at manufacture. Look for a valid Health Canada NPN. Bio-K+ Women's Health Capsules contain Lacticaseibacillus rhamnosus GR-1™ and Limosilactobacillus reuteri RC-14™, 2 billion live bacteria guaranteed until expiry. Take 1 capsule 1–2 times daily.
In Canada, probiotic products are regulated as Natural Health Products; each must hold an approved NPN and carry only authorized claims. No Canadian probiotic has a Health Canada-approved claim to treat, prevent, or manage BV. Approved claims cover maintaining healthy vaginal flora and reducing yeast and bacteria on vaginal surfaces. Bio-K+ Women's Health Capsules carry authorized Health Canada claims. The clinical research on this page is science education, not a product claim.
Clinical research has studied certain Lactobacillus strains, particularly GR-1™ and RC-14™, in the context of BV, with some trials showing improved vaginal flora outcomes alongside antibiotic treatment. Results are mixed and not uniform across all populations. Probiotics are not a replacement for antibiotic therapy. Always consult a healthcare provider for diagnosis and treatment of BV.
Lacticaseibacillus rhamnosus GR-1™ and Limosilactobacillus reuteri RC-14™ are the most extensively studied probiotic strains in published vaginal health research, with more than 25 clinical trials documented. Look for full strain designations, CFU guaranteed until expiry, and a valid Health Canada NPN. No probiotic holds a Health Canada-approved claim for BV treatment. Consult a healthcare provider for personalized guidance.
Lactobacillus rhamnosus strains, particularly GR-1™, produce lactic acid that contributes to an acidic vaginal pH, adhere to vaginal epithelial cells, and have been studied for their interaction with vaginal flora in the context of BV. Clinical research shows mixed results; some trials demonstrate improved vaginal flora outcomes, while others find no significant difference compared to placebo.
In clinical studies, changes in vaginal microbiome composition have been assessed at 30-day and 90-day intervals following consistent daily use. Results vary by individual, strain, dose, and existing vaginal microbiome composition. Consistent daily use reflects the methodology used in published research; occasional use does not. Consult a healthcare provider for personal guidance.
Some clinical research has studied Lactobacillus probiotics alongside antibiotic therapy for BV, with some trials showing improved outcomes at day 30 compared to antibiotics alone. The decision to use a probiotic alongside prescribed antibiotic treatment should always be made in consultation with a healthcare provider. No Canadian probiotic holds a Health Canada-approved claim for use alongside antibiotics for BV.
Suis @biokplus et tague-nous pour être mentionné.e.
